Vanguard Group Inc. Acquires 97,536 Shares of Moderna, Inc. (NASDAQ:MRNA)

Vanguard Group Inc. grew its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 0.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 40,323,750 shares of the company's stock after acquiring an additional 97,536 shares during the quarter. Vanguard Group Inc. owned 10.48% of Moderna worth $1,676,662,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in MRNA. State Street Corp lifted its stake in shares of Moderna by 12.1% in the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company's stock valued at $1,125,899,000 after acquiring an additional 1,823,276 shares during the last quarter. Geode Capital Management LLC raised its position in Moderna by 2.6% in the third quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company's stock valued at $470,670,000 after purchasing an additional 178,115 shares during the last quarter. Wellington Management Group LLP raised its position in Moderna by 21.0% in the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company's stock valued at $349,166,000 after purchasing an additional 906,114 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Moderna by 0.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company's stock valued at $260,023,000 after purchasing an additional 19,819 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Moderna by 6.2% during the third quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company's stock worth $205,431,000 after purchasing an additional 178,939 shares during the last quarter. Institutional investors own 75.33% of the company's stock.

Moderna Price Performance

Shares of MRNA traded down $2.77 during trading hours on Monday, hitting $28.35. The stock had a trading volume of 20,439,330 shares, compared to its average volume of 6,871,990. The firm has a 50 day simple moving average of $34.60 and a 200-day simple moving average of $43.84. Moderna, Inc. has a 1-year low of $26.80 and a 1-year high of $170.47. The firm has a market capitalization of $10.96 billion, a P/E ratio of -3.05 and a beta of 1.86.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on MRNA. Argus lowered shares of Moderna from a "buy" rating to a "hold" rating in a report on Wednesday, December 18th. Berenberg Bank raised their price target on shares of Moderna from $33.00 to $42.00 and gave the company a "hold" rating in a research note on Thursday, January 16th. Morgan Stanley reduced their price objective on shares of Moderna from $70.00 to $38.00 and set an "equal weight" rating on the stock in a research note on Wednesday, January 15th. Leerink Partners decreased their price objective on Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a report on Thursday, January 16th. Finally, Bank of America cut their target price on Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a report on Tuesday, February 11th. Four analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Moderna has an average rating of "Hold" and an average target price of $59.00.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.